Normal Tension Glaucoma Treatment and Supportive Care

What Is Normal Tension Glaucoma?

Normal tension glaucoma, also called NTG or normal pressure glaucoma, is a form of open-angle glaucoma in which the optic nerve and retinal nerve fiber layer are damaged even though intraocular pressure is within the statistically normal range. This makes NTG one of the most clinically important examples of why glaucoma cannot be understood through eye pressure alone. Eye pressure remains important and requires regular ophthalmic monitoring, but in NTG the optic nerve may be vulnerable because of additional factors such as impaired ocular blood flow, reduced perfusion pressure, vascular dysregulation, mitochondrial dysfunction, oxidative stress, inflammation, neurotrophin deprivation, autonomic imbalance, sleep-related hypoxia, and systemic vascular terrain.

Netra Restoration Therapy, or NRT, is Netra's integrative supportive-care program. It is not a cure or a treatment for glaucoma, and it does not replace ophthalmic diagnosis, imaging, visual field monitoring, or prescribed medical care. Some patients choose it alongside their eye doctor's care for help with general health factors such as sleep, stress and diet.

The key clinical insight in normal tension glaucoma is simple but powerful: the optic nerve may be damaged even when pressure readings look acceptable. That observation naturally leads to a systems-biology question. What makes one optic nerve more vulnerable than another? Why does damage occur in the presence of normal measured pressure? Why do some patients progress despite apparently controlled pressure? These questions are still being researched.

Normal Tension Glaucoma Treatment: What Standard Eye Care Involves

Standard treatment for normal tension glaucoma lowers eye pressure, even though it already measures in the normal range. In the Collaborative Normal-Tension Glaucoma Study, the aim was a 30% drop from each treated eye’s own starting pressure. Eye drops, laser treatment and surgery are all used. Your eye doctor may also ask about your blood pressure, especially at night, and about sleep apnea, because both may affect blood flow to the optic nerve. Netra Restoration Therapy, described further down this page, is meant to be used alongside this care, not instead of it.

How normal tension glaucoma is diagnosed

Most people have no symptoms early on. The condition is usually found at a routine eye exam, when the optic nerve looks damaged or a visual field test shows a blind spot. The tests are the same ones used for other open-angle glaucoma:

• A dilated exam of the optic nerve, often with photos, and an OCT scan that measures the nerve fiber layer.
• A visual field test to map any blind spots.
• A corneal thickness measurement. A thin cornea can make eye pressure read lower than it really is.
• Gonioscopy and a close look at the front of the eye with a slit lamp. Gonioscopy checks that the eye’s drainage angle is open. Angle closure, pigment dispersion, exfoliation and inflammation inside the eye can all cause glaucoma even when the pressure reads normal at the visit.
• Several pressure readings at different times of day. Eye pressure is often highest in the early morning.

Two findings are more common in normal tension glaucoma than in high-pressure glaucoma: small bleeds at the edge of the optic nerve (disc hemorrhages), and blind spots close to the center of vision, more often in the upper half of what you see.

Your doctor will also ask about steroid use, eye injuries and eye surgery. These can raise eye pressure for a time, so the damage may have happened while the pressure was high. They will also ask about episodes of very low blood pressure, for example after major surgery, trauma or sepsis. A one-off drop in blood flow like this can leave optic nerve damage that looks like normal tension glaucoma but doesn’t keep getting worse.

If something doesn’t fit the usual pattern, your doctor may order an MRI scan to rule out a growth pressing on the visual pathway, such as a pituitary tumor. Warning signs include a young person with no family history of glaucoma, damage in only one eye, fast worsening, a bulging eye, a pale optic nerve without cupping, field loss that stops sharply at the up-and-down line through the center of vision, or other neurological symptoms.

When treatment starts

Not every eye with normal tension glaucoma gets worse, and many change slowly. In the Collaborative Normal-Tension Glaucoma Study, about one-third of people followed without treatment showed visual field worsening within 3 years, and about half within 5 to 7 years. The change was usually small and slow.

So some eye doctors, after talking it through with you, start by watching closely with repeat OCT scans and visual field tests, and begin treatment once worsening is confirmed. Treatment is more likely to start right away when damage is already moderate or advanced, when blind spots threaten central vision or when there are several risk factors. In the same study, migraine and disc hemorrhages were linked to faster worsening. Being female may also play a part, but that link was weaker and could have been due to chance. Other research has linked larger swings in eye pressure over the day to faster worsening.

Lowering eye pressure

Lowering eye pressure is the only treatment shown to slow normal tension glaucoma. In the Early Manifest Glaucoma Trial, which included people with high and normal eye pressure, treatment slowed glaucoma in both groups.

The Collaborative Normal-Tension Glaucoma Study only assigned eyes to treatment or no treatment if they were already getting worse, had a new disc hemorrhage, or had blind spots threatening the center of vision. When every eye was counted, the treated and untreated groups did not clearly differ: 33% of treated eyes got worse compared with 39% of untreated eyes. Cataracts were more common in treated eyes, mostly after glaucoma surgery, and can make field tests look worse. When the researchers stopped counting eyes once a cataract had blurred their vision, 12% of treated eyes got worse compared with 27% of untreated eyes. Their conclusion was that lowering pressure helps, as long as the treatment doesn’t cause cataracts.

The options are the same as for other open-angle glaucoma:

• Eye drops. Prostaglandin analog drops are a common first choice. Our guide to glaucoma eye drops covers the types and side effects.
• Laser. Selective laser trabeculoplasty (SLT) can lower eye pressure by a modest amount even when it is already in the normal range.
• Surgery. If the disease keeps getting worse despite drops or laser, or the pressure has to go very low, trabeculectomy is often needed. It also makes a cataract more likely. The role of minimally invasive glaucoma surgery (MIGS) in normal tension glaucoma is still debated. See our guide to glaucoma surgery and laser.

One drop has drawn extra interest. In the Low-Pressure Glaucoma Treatment Study (low-pressure glaucoma is another name for normal tension glaucoma), 9% of people using brimonidine had visual field worsening over an average of about 2.5 years, compared with 39% of those using timolol, even though eye pressure was similar in both groups. But more people on brimonidine stopped because of side effects such as eye allergy (28% compared with 11%), and a Cochrane review rated the evidence as very low certainty. So it hasn’t been proven that brimonidine protects the nerve.

Blood pressure, sleep and blood flow

Low blood pressure at night may reduce blood flow to the optic nerve. In one study of 85 people with normal tension glaucoma, the longer their blood pressure stayed 10 mmHg or more below their usual daytime level while they slept, the more likely their visual field was to get worse over the next 12 months.

If your glaucoma keeps getting worse even though your eye pressure is controlled, your eye doctor may suggest a 24-hour blood pressure check. If it shows big drops while you sleep, your eye doctor may ask the doctor who prescribes your blood pressure medicine whether the dose or timing should change. That decision is for your prescribing doctor. Don’t stop, skip or move any dose on your own. Blood pressure that stays high can lead to heart attack, stroke, heart failure and kidney failure.

Sleep apnea is also thought to affect blood flow to the optic nerve, so your doctor may ask a few screening questions about it.

No treatment aimed at blood flow or other factors outside eye pressure has yet been proven to slow normal tension glaucoma. Researchers are studying several, including nicotinamide (vitamin B3) and ginkgo biloba. Check with your doctor before trying either one: the nicotinamide doses in these studies are far higher than in ordinary vitamins, and ginkgo may raise the risk of bleeding if you take a blood thinner. Lowering eye pressure remains the core of care.

Regular exercise is good for your overall health and shouldn’t be avoided. But don’t hold head-down yoga poses such as headstands or downward dog for long, because they can raise eye pressure a lot. And don’t smoke.

Follow-up visits

Your doctor will usually set a target pressure based on how much damage there is, which part of your visual field is affected and what your pressure was before treatment. Repeat visual field tests and OCT scans then show whether the target is right and the disease is stable. Some people with normal tension glaucoma later develop high eye pressure, which is one more reason to keep regular visits.

For the bigger picture, see our guides to the types of glaucoma and glaucoma.

Factors Beyond Eye Pressure That Researchers Are Studying

Researchers think several factors besides eye pressure may play a part in normal tension glaucoma. They include the optic nerve head, the retinal ganglion cells and their long fibers (axons), blood flow to the eye, blood pressure, the lining of blood vessels, cell energy (mitochondria), inflammation, oxidative stress, and the nervous system's control of blood vessels. None of these has yet led to a proven treatment for normal tension glaucoma, so lowering eye pressure remains the core of care.

Areas under study include:

• Blood flow to the eye and optic nerve
• Neuroprotection: ways to help retinal ganglion cells survive
• Cell energy (mitochondria) and the clearing of damaged mitochondria (mitophagy)
• Oxidative and nitrosative stress
• Inflammation and the eye's immune cells (microglia)
• Nerve growth factors such as BDNF and NGF
• Stress, the autonomic nervous system and blood vessel tone
• Blood pressure patterns and the health of blood vessel linings
• Retinal metabolism and cell repair
• Links between gut bacteria, the immune system and the eye

This systems-based framework is especially relevant for NTG because many patients have risk patterns that are not fully explained by eye pressure. Published reviews describe NTG as a multifactorial disease in which intraocular-pressure-independent factors play an important role, including ocular blood flow abnormalities, Flammer syndrome, vascular dysregulation, and oxidative stress. The Collaborative Normal-Tension Glaucoma Study also showed that progression is variable: some patients progress while others remain stable for years, and risk factors such as disc hemorrhage and migraine history have been associated with faster progression, with a weaker link for female sex.

Researchers think the optic nerve depends on more than eye pressure. It also needs a steady supply of blood, oxygen and nutrients, healthy support cells, enough cell energy, and growth factor signals. When these are under strain, the optic nerve may be more easily damaged, even at eye pressures that would not harm another eye.

Why Researchers Look Beyond Eye Pressure in Normal Tension Glaucoma

Researchers study normal tension glaucoma as a condition with several possible causes because the optic nerve is damaged even though measured eye pressure is normal. This does not mean pressure is irrelevant, and lowering it is still the only proven treatment. It does mean that pressure alone may not fully explain why some optic nerves are more vulnerable than others.

Looking beyond eye pressure is not an argument against conventional ophthalmology. It is an argument for broader understanding. Modern glaucoma care is excellent at identifying optic nerve cupping, retinal nerve fiber layer thinning, ganglion cell complex loss, and visual field defects. These tests show what has happened structurally and functionally. Researchers are also asking another question: what vascular, metabolic, inflammatory, mitochondrial, neurologic, and systemic factors may be contributing to ongoing vulnerability? These questions are still open, and none of them has yet led to a proven treatment.

Ocular Blood Flow and Perfusion Instability

The optic nerve head is metabolically active neural tissue. Retinal ganglion cell axons require continuous oxygen and nutrient delivery. In NTG, multiple studies and reviews have emphasized impaired ocular blood flow, disturbed autoregulation, reduced perfusion pressure, and vascular dysregulation as important contributors. If blood flow is unstable, the optic nerve may experience repeated episodes of mild ischemia or reperfusion injury. These fluctuations can increase oxidative stress, mitochondrial strain, and axonal vulnerability.

Because blood flow may play a part in normal tension glaucoma, your eye doctor may ask about migraine, cold hands and feet, low blood pressure and sleep. These questions help describe your risk. No treatment aimed at blood flow has yet been proven to slow normal tension glaucoma.

Nocturnal Hypotension and Reduced Ocular Perfusion Pressure

Some NTG patients may experience blood pressure drops during sleep. If systemic blood pressure falls too low at night, ocular perfusion pressure may decline. The optic nerve may then receive less blood flow during the exact hours when the patient is unaware of any problem. Prospective studies have linked nocturnal hypotension and low nocturnal diastolic ocular perfusion pressure with visual field progression in NTG. This makes systemic vascular rhythm an important part of the biological terrain.

Questions about blood pressure medicine belong with the doctor who prescribes it. At Netra, supportive care can include general advice on sleep, stress and daily habits, but it does not change blood pressure treatment and it is not a glaucoma treatment.

Vascular Dysregulation and Flammer Syndrome

Flammer syndrome describes a phenotype of primary vascular dysregulation in which blood vessels respond abnormally to stimuli such as cold, emotional stress, or hypoxia. It has been associated with cold hands and feet, low blood pressure, migraine tendency, altered sensitivity to stress, and disturbed ocular blood flow. The relationship between Flammer syndrome and normal tension glaucoma has been discussed extensively in ophthalmology literature.

In biomedical terms, this framework is important because the optic nerve requires stable autoregulation. If vascular tone is unstable, small changes in blood pressure or eye pressure may produce larger fluctuations in oxygen delivery. No treatment aimed at vascular dysregulation has been proven to protect the optic nerve.

Mitochondrial Dysfunction and Energy Failure

Retinal ganglion cells have long axons and high energy demand. Their axons pass through the optic nerve head and must maintain axonal transport over long distances. Mitochondria provide the energy required for this process. When mitochondrial function declines, retinal ganglion cells may become more sensitive to vascular stress, oxidative injury, inflammation, and mechanical strain.

Glaucoma research increasingly recognizes mitochondrial dysfunction and impaired mitophagy as important contributors to retinal ganglion cell degeneration. High-dose nicotinamide (vitamin B3), which supports cell energy, is being tested in glaucoma trials, but it is not yet a proven treatment.

Oxidative Stress and Nitrosative Stress

Oxidative stress occurs when reactive oxygen species exceed the antioxidant capacity of the tissue. In NTG, impaired ocular blood flow and vascular dysregulation may create repeated ischemia-reperfusion stress, increasing oxidative and nitrosative burden. Oxidative injury can damage mitochondria, lipids, proteins, DNA, and axonal structures.

There is no good evidence yet that antioxidant supplements slow glaucoma.

Inflammation, Microglial Activation, and Cytokines

Glaucoma is increasingly understood as a neurodegenerative optic neuropathy with immune and inflammatory components. Microglial activation, astrocyte reactivity, complement signaling, and inflammatory cytokines may contribute to retinal ganglion cell stress. Cytokines such as TNF-alpha, IL-1 beta, and IL-6 are frequently discussed in neurodegeneration and retinal injury because they can influence mitochondrial function, oxidative stress, vascular regulation, and cell death pathways.

So far this is mainly laboratory and animal research. No anti-inflammatory medicine or supplement has been shown to protect the optic nerve in people with glaucoma.

Neurotrophin Deprivation and Axonal Transport Stress

Retinal ganglion cells depend on neurotrophic support. Brain-derived neurotrophic factor, or BDNF, and nerve growth factor, or NGF, are important in neural survival and repair signaling. In glaucoma, impaired axonal transport may reduce the delivery of neurotrophic support from brain targets back to retinal ganglion cells. This can weaken cell survival signaling and increase vulnerability to degeneration.

Treatments based on these growth factors are still experimental. Early trials of nerve growth factor eye drops in glaucoma have mainly tested safety.

Excitotoxicity and Glutamate-Mediated Injury

Excitotoxicity refers to injury caused by excessive glutamate signaling and calcium overload in neural tissue. Glutamate excitotoxicity has been investigated in retinal ganglion cell distress and glaucoma-related neurodegeneration. It may interact with mitochondrial dysfunction, oxidative stress, inflammation, and impaired glial support.

Two large trials of memantine, a medicine that blocks the effects of excess glutamate, did not slow glaucoma.

Ferroptosis and Lipid Peroxidation

Ferroptosis is an iron-dependent form of regulated cell death driven by lipid peroxidation. Recent glaucoma research has described ferroptosis as a possible contributor to retinal ganglion cell death, especially in settings of oxidative stress, mitochondrial dysfunction, iron imbalance, and antioxidant depletion. Much of this evidence remains preclinical or mechanistic.

For now it is a research idea, not a basis for treatment.

Autonomic Dysfunction and Stress Physiology

The autonomic nervous system influences heart rate variability, blood pressure rhythm, vascular tone, and microcirculation. Several studies have explored autonomic dysfunction and heart rate variability in normal tension glaucoma. Reduced autonomic flexibility may contribute to unstable ocular perfusion, nocturnal vascular changes, and reduced ability of the body to adapt to stress. These links are still being studied, and it is not known whether improving them changes the course of normal tension glaucoma.

Key Biological Mechanisms in Normal Tension Glaucoma

Retinal Ganglion Cell Degeneration

The central cellular event in glaucoma is the progressive injury and loss of retinal ganglion cells and their axons. These cells carry visual information from the retina to the brain through the optic nerve. When ganglion cells are damaged, visual field defects develop. In NTG, this process occurs without consistently elevated eye pressure, which suggests that retinal ganglion cells may be unusually vulnerable to non-pressure stressors.

Optic Nerve Head Vulnerability

The optic nerve head is a critical pressure, vascular, and metabolic interface. Retinal ganglion cell axons pass through the lamina cribrosa, where they may be vulnerable to impaired perfusion, structural strain, axonal transport disruption, glial activation, and mitochondrial stress. In NTG, the optic nerve head may be sensitive to pressure levels that appear normal on paper because the tissue environment is less resilient.

Axonal Transport Dysfunction

Retinal ganglion cells depend on axonal transport to move mitochondria, proteins, signaling molecules, and neurotrophic factors along the optic nerve. Disrupted axonal transport may reduce survival signaling and contribute to progressive degeneration. Blood-flow instability, mitochondrial dysfunction, inflammation, and mechanical stress can all impair axonal transport.

Ocular Blood Flow Reduction

Abnormal ocular blood flow is one of the most important non-pressure mechanisms in NTG. Research has linked NTG with reduced optic nerve head perfusion, vascular dysregulation, impaired autoregulation, and abnormal response to systemic blood pressure changes. Since the optic nerve is highly dependent on stable oxygen delivery, even subtle perfusion deficits may become clinically important over time.

Endothelial Dysfunction

The endothelium regulates vascular tone, nitric oxide signaling, inflammation, thrombosis, and microvascular responsiveness. Endothelial dysfunction may contribute to unstable blood flow and impaired autoregulation. In NTG, endothelial and vascular factors are especially relevant because the disease can occur without high pressure.

Mitochondrial Dysfunction

Mitochondria are central to retinal ganglion cell survival. They provide ATP, regulate calcium, influence oxidative stress, and participate in cell death signaling. Mitochondrial dysfunction can make optic nerve tissue less able to withstand low perfusion, inflammation, oxidative stress, or excitotoxic injury.

Oxidative Stress

Oxidative stress may be generated by ischemia-reperfusion, mitochondrial failure, chronic inflammation, sleep-related hypoxia, and systemic metabolic imbalance. In the optic nerve, oxidative stress can damage mitochondria and axons, amplify glial activation, and increase retinal ganglion cell vulnerability.

Neuroinflammation

Neuroinflammation in glaucoma involves retinal microglia, astrocytes, complement pathways, and cytokine signaling. While inflammation can begin as a protective response, chronic activation may become damaging. These findings come mainly from laboratory and animal research.

BDNF and NGF Signaling

BDNF and NGF are neurotrophins that help maintain neural survival and plasticity. In glaucoma, impaired neurotrophin signaling may contribute to retinal ganglion cell death. BDNF-mediated neuroprotection is an active area of glaucoma research, although translating neurotrophin biology into clinical therapy remains challenging.

Gut-Eye Axis and Immune-Metabolic Terrain

The gut-eye axis is an emerging field. Reviews have described potential links between gut microbiota, immune regulation, systemic inflammation, molecular mimicry, metabolites, and glaucoma progression. This evidence is still developing and should not be overstated. It is too early to use it to guide glaucoma treatment.

Netra Restoration Therapy: Supportive Care Alongside Glaucoma Treatment

Netra Restoration Therapy (NRT) is Netra's integrative supportive-care program. It is not a glaucoma treatment. It is not a way to lower eye pressure, and no study has shown that it slows normal tension glaucoma or protects the optic nerve. People who choose it use it alongside the treatment and monitoring their eye doctor provides.

NRT may include acupuncture, Traditional Chinese Medicine and Ayurvedic approaches, herbal products, nutrition advice, and guidance on sleep, stress and daily habits. Plans are tailored to each person's general health and medical history. If you take herbs or supplements, tell your eye doctor and your primary care doctor, because some can interact with medicines or affect blood pressure or bleeding. Some Ayurvedic products have been found to contain lead, mercury or arsenic, so ask where any product comes from and whether it has been independently tested for these metals.

NRT does not replace glaucoma monitoring or treatment, and it does not replace urgent care for new vision symptoms. It cannot reverse optic nerve damage.

Regular eye pressure checks, OCT scans and visual field tests with your eye-care team, with pressure-lowering treatment when needed, remain the core of normal tension glaucoma care. Supportive care at Netra focuses on general health habits, not on treating the optic nerve.

Other Approaches and What the Evidence Shows

Blood Flow and Circulation

The optic nerve depends on a steady blood supply, and small changes in blood pressure or blood vessel control may matter more in normal tension glaucoma. No treatment aimed at blood flow has yet been proven to slow the disease, and NRT is not a treatment for blood flow to the eye.

Stress and Sleep

Stress affects heart rate, blood pressure and sleep. Supportive care may include help with stress and sleep habits. This can help your general health, but it has not been shown to slow normal tension glaucoma. If you snore loudly, or someone notices that you stop breathing or gasp while you sleep, ask your doctor about a sleep apnea test.

Cell Energy (Mitochondria)

Retinal ganglion cells use a lot of energy. High-dose nicotinamide (vitamin B3), which supports cell energy, is being tested in glaucoma trials but is not yet proven. Don't start high-dose supplements without asking your eye doctor, because high doses can harm the liver.

Antioxidants and Diet

Oxidative stress may link blood flow problems, mitochondrial strain and inflammation. A diet rich in vegetables and fruit is good for your general health, but there is no good evidence yet that antioxidant supplements slow glaucoma.

Inflammation

Long-lasting, low-grade inflammation may make retinal ganglion cells more vulnerable. This is mainly laboratory research, and no anti-inflammatory approach has been shown to protect the optic nerve in people with glaucoma.

Nerve Growth Factors

The optic nerve is part of the central nervous system. Growth factors such as BDNF and NGF help nerve cells survive. Treatments based on them are still experimental.

Gut Health

Early studies suggest signals from the gut may affect the immune system and the eye, but this has not led to any glaucoma treatment. It is too early to use gut health to guide care.

Translating Traditional Medicine into Modern Biological Language

Traditional Chinese Medicine may describe NTG through patterns such as Liver and Kidney deficiency, Blood Stasis, Qi deficiency, Yin deficiency, or internal wind. These should not be presented as exact biomedical diagnoses. They can be interpreted as traditional frameworks that may loosely parallel impaired tissue nourishment, vascular insufficiency, reduced repair capacity, neurodegenerative aging, autonomic instability, or chronic stress physiology.

Ayurvedic concepts such as Vata, Pitta, Kapha, Majja Dhatu, Rakta Dhatu, and Ojas may be used as traditional interpretive frameworks related to nervous system regulation, inflammation, circulation, tissue nourishment, and resilience. Again, these are conceptual parallels rather than direct scientific definitions.

Herbal formulas can contain many active compounds, and researchers are studying how they act in the body. No herbal product has been proven to slow glaucoma. Some herbs can interact with medicines or affect blood pressure or bleeding, so tell your doctors about any you take.

Frequently Asked Questions on Normal Tension Glaucoma

Selected References for Scientific Support

• Gosling D, Meyer JJ. Normal Tension Glaucoma. StatPearls. NCBI Bookshelf. Updated medical overview of NTG definition, evaluation, and risk considerations.
• Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. American Journal of Ophthalmology. 1998;126(4):487-497.
• Anderson DR. Collaborative normal tension glaucoma study. Current Opinion in Ophthalmology. 2003;14(2):86-90.
• Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. American Journal of Ophthalmology. 1998;126(4):498-505.
• Anderson DR, Drance SM, Schulzer M; Collaborative Normal-Tension Glaucoma Study Group. Natural history of normal-tension glaucoma. Ophthalmology. 2001;108(2):247-253.
• Drance S, Anderson DR, Schulzer M; Collaborative Normal-Tension Glaucoma Study Group. Risk factors for progression of visual field abnormalities in normal-tension glaucoma. American Journal of Ophthalmology. 2001;131(6):699-708.
• Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M; Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Archives of Ophthalmology. 2002;120(10):1268-1279.
• Krupin T, Liebmann JM, Greenfield DS, Ritch R, Gardiner S; Low-Pressure Glaucoma Study Group. A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study. American Journal of Ophthalmology. 2011;151(4):671-681.
• Sena DF, Lindsley K. Neuroprotection for treatment of glaucoma in adults. Cochrane Database of Systematic Reviews. 2017;1:CD006539. doi:10.1002/14651858.CD006539.pub4.
• Radhakrishnan S. Normal-Tension Glaucoma. Glaucoma Research Foundation. Updated August 8, 2024. glaucoma.org/types/normal-tension-glaucoma.
• Williams RD. Normal-Tension Glaucoma: What You Need to Know. Glaucoma Research Foundation. August 8, 2024. glaucoma.org/articles/normal-tension-glaucoma-what-you-need-to-know.
• National Center for Complementary and Integrative Health. Ginkgo. NCCIH. Updated February 2025.
• MedlinePlus. High Blood Pressure. National Library of Medicine. Updated January 22, 2026.
• Wu X, et al. Role of ocular blood flow in normal tension glaucoma. Clinical Ophthalmology. 2022; review focused on abnormal ocular blood flow, Flammer syndrome, vascular dysregulation, and oxidative stress in NTG.
• Fan N, et al. Ocular blood flow and normal tension glaucoma. BioMed Research International. 2015; review of disturbed ocular blood flow, vasospasm, small-vessel disease, and ocular perfusion in NTG.
• Charlson ME, et al. Nocturnal systemic hypotension increases the risk of glaucoma progression. Ophthalmology. 2014; prospective longitudinal study linking nocturnal hypotension with visual field progression in NTG.
• Raman P, et al. Low nocturnal diastolic ocular perfusion pressure as a risk factor for normal-tension glaucoma progression. Eye. 2018; prospective evidence supporting the relevance of systemic perfusion parameters.
• Konieczka K, et al. Flammer Syndrome. EPMA Journal. 2014; review describing primary vascular dysregulation and the clinical phenotype now called Flammer syndrome.
• Konieczka K, et al. Relationship between normal tension glaucoma and Flammer syndrome. EPMA Journal. 2017; review discussing the association between NTG, ocular blood flow, and primary vascular dysregulation.
• Kurysheva NI, et al. Heart rate variability in normal tension glaucoma: a case-control study. Medicine. 2018; study exploring autonomic dysfunction and HRV patterns in NTG.
• Lambuk L, et al. Brain-derived neurotrophic factor-mediated neuroprotection in glaucoma. International Journal of Molecular Sciences. 2022; review of BDNF and retinal ganglion cell survival biology.
• Vernazza S, et al. Risk factors for retinal ganglion cell distress in glaucoma and neuroprotective potential. International Journal of Molecular Sciences. 2021; review discussing mitochondrial dysfunction, glutamate excitotoxicity, inflammatory cytokines, and axonal transport.
• Stavropoulos D, et al. The role of mitophagy in glaucomatous neurodegeneration. Cells. 2023; review of mitochondrial quality control and retinal ganglion cell vulnerability.
• Qin M, et al. Ferroptosis and retinal ganglion cell death in glaucoma. 2025; review examining iron-dependent lipid peroxidation and ferroptosis mechanisms in glaucomatous neurodegeneration.
• Chen J, et al. The role of gut microbiota in glaucoma progression and pathogenesis. 2023; review of gut-retina axis concepts, immune signaling, and microbial changes in glaucoma.
• Ullah Z, et al. The role of gut microbiota in the pathogenesis of glaucoma. 2024; review of gut microbiome, immune modulation, and glaucoma mechanisms.